Alpha Family Trust Takes Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Alpha Family Trust acquired a stake of 740 shares in Thermo Fisher Scientific, valued at approximately $368,000, according to a recent SEC filing.
• Several institutional investors, including Brighton Jones LLC and Revolve Wealth Partners LLC, have significantly increased their holdings in Thermo Fisher Scientific during the previous quarter.
• Thermo Fisher Scientific reported quarterly earnings of $5.36 per share, surpassing estimates, along with a revenue of $10.86 billion, reflecting a 2.9% year-over-year increase.

Alpha Family Trust acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 740 shares of the medical research company's stock, valued at approximately $368,000.

Several other institutional investors also recently made changes to their positions in the stock. Brighton Jones LLC lifted its holdings in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after acquiring an additional 988 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares in the last quarter. Bank Pictet & Cie Europe AG lifted its holdings in Thermo Fisher Scientific by 0.3% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock worth $79,677,000 after buying an additional 461 shares in the last quarter. First Trust Advisors LP lifted its holdings in Thermo Fisher Scientific by 17.4% in the 4th quarter. First Trust Advisors LP now owns 36,602 shares of the medical research company's stock worth $19,042,000 after buying an additional 5,438 shares in the last quarter. Finally, Curi RMB Capital LLC lifted its holdings in Thermo Fisher Scientific by 2.4% in the 4th quarter. Curi RMB Capital LLC now owns 17,901 shares of the medical research company's stock worth $9,313,000 after buying an additional 418 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at $52,037,916.68. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,400 shares of company stock worth $8,345,792 in the last quarter. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

TMO opened at $489.96 on Monday. The company's 50-day moving average price is $434.83 and its 200 day moving average price is $459.02. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The firm has a market cap of $185.01 billion, a price-to-earnings ratio of 28.34, a price-to-earnings-growth ratio of 2.61 and a beta of 0.74. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business earned $5.37 earnings per share. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Robert W. Baird boosted their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. HSBC reissued a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Raymond James Financial restated an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Argus cut their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $593.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.